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Cigarette smoking is a major risk factor for coronary as well
as peripheral vascular disease and stroke. The general
mechanisms by which cigarette smoking accelerates athero-
sclerosis and causes acute cardiovascular events are believed
to include adverse effects on lipids, endothelial damage or
dysfunction, hemodynamic stress, oxidant injury, neutrophil
activation, enhanced thrombosis and increased fibrinogen
and blood viscosity (1). Although there are several thousand
potentially toxic chemicals in cigarette smoke, there has
been persistent concern that nicotine has direct injurious
effects on the cardiovascular system. Many smokers who are
trying to quit, as well as their physicians, are afraid of the
potential toxicity of nicotine. This fear results in physicians
failing to prescribe nicotine and patients not using or using
too little nicotine to optimally aid smoking cessation.
Several lines of evidence indicate that nicotine is not a direct
cause of tobacco-related cardiovascular disease (other than
by sustaining tobacco addiction, of course).
One line of evidence includes epidemiologic studies of
the health consequences of smokeless tobacco use, where
there is systemic absorption of nicotine but no absorption of
other combustion products. The daily level of exposure to
nicotine from smokeless tobacco has been shown to be
similar to that from cigarette smoking (2,3). It must be
noted, however, that with cigarette smoking nicotine is
delivered intermittently into the pulmonary circulation,
resulting in transiently high levels of nicotine in arterial
blood, exceeding manyfold those levels seen in blood when
nicotine is dosed gradually from smokeless tobacco or pipe
smoking (4). Rapid delivery of nicotine through cigarette
smoke is expected to produce more deleterious effects on the
arterial circulation than nicotine absorbed more slowly
through the buccal mucosa, as is the case with the use of
snuff. For this reason, safety data from smokeless tobacco
studies cannot entirely exclude a contribution of nicotine
from cigarette smoking to cardiovascular disease.
See page 1784
Huhtasaari et al. (5,6) have published two case-control
studies of myocardial infarction among residents of north-
ern Sweden who participated in the World Health Orga-
nization MONICA (Multinational Monitoring of Trends
and Determinants in Cardiovascular Disease) Project. The
second study, published in this issue of the Journal, included
687 men, 25 to 64 years old, who presented with their first
acute myocardial infarction or sudden death, studied be-
tween 1991 and 1993 (5). These patients were compared
with age-matched and place-of-living–matched control
subjects. The earlier study involved 585 men, 35 to 64 years
old, with acute myocardial infarction, compared with ran-
domly selected control subjects, studied between 1989 and
1991 (6). Neither study found evidence of an increased risk
of myocardial infarction or sudden death in regular snuff
users, although both studies confirmed the known effect of
cigarette smoking to increase the risk of myocardial infarc-
tion. In contrast, a prospective cohort study involving
construction workers from all of Sweden has reported that
regular snuff use incurs a significant increased risk of
mortality from ischemic heart disease (7). Data on tobacco
use in this cohort study were collected during a medical
examination between 1971 and 1974, with follow-up for
cause-specific mortality between 1974 and 1985. It is
unclear why the results of the case-control and prospective
studies differ. In comparing the studies, it was found that
the study groups were different, the prevalence of snuff use
in the groups was different, the years during which the
studies were conducted were different, the tobacco use
exposure over the course of the risk years before the event
may have been different and the methods for ascertaining
end points were different. Perhaps one or more of these
differences may explain the discrepant results.
In support of the conclusions of the case-control studies
indicating that the use of snuff is not associated with
increased cardiovascular risk, are experimental studies of the
physiologic effects of smokeless tobacco and transdermal
nicotine. The later studies specifically address the question
of whether nicotine contributes to thrombosis, which is an
important, if not the most important, mechanism for
smoking-induced acute cardiovascular events. The marker
of the prothrombotic effect was urinary excretion of a
metabolite of thromboxane A2, which is an indication of in
vivo platelet activation. Snuff users and cigarette smokers
with similar blood levels of cotinine, a biomarker for
nicotine intake, showed no difference in urinary excretion of
thromboxane A2 metabolites as compared with snuff users
and those who do not use tobacco at all, whereas smokers
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had increased levels of thromboxane A2 metabolite excre-
tion (2). Similar results using thromboxane A2 metabolite
excretion were found in a crossover study comparing smok-
ers when they were smoking cigarettes, using transdermal
nicotine or placebo patch (8).
Studies of nicotine medication to aid smoking cessation
also support the proposition that nicotine does not substan-
tially contribute to acute cardiovascular events. Two pro-
spective studies involving treatment of patients with known
cardiovascular disease with transdermal nicotine have been
published (9,10). Neither found evidence that transdermal
nicotine increased the risk of acute cardiovascular events as
compared with placebo treatment. In addition, the Health
Lung study involved treating .3,000 middle-aged smokers
with chronic obstructive pulmonary disease with nicotine
gum (11). Over five years, nicotine gum users were found to
have lower hospital admission rates for cardiovascular dis-
ease as compared with those who quit smoking without
using nicotine gum, and in both cases they had lower rates
as compared with individuals who continued to smoke with
or without using gum. Finally, an experimental study
showed that patients with severe coronary artery disease
treated with transdermal nicotine, which suppressed but did
not eliminate smoking, resulted in a substantial reduction in
the exercise-induced myocardial perfusion defect size stud-
ied by quantitative thalium-201 single-photon emission
computed tomography (12). Improved perfusion was noted
despite a twofold increase in nicotine levels while using
patches and smoking at the same time, as compared with
the baseline smoking alone condition. It is likely that the
improved perfusion was due to reduced exposure to carbon
monoxide and other combustion products.
Overall, the epidemiologic and experimental data suggest
that nicotine absorbed from smokeless tobacco, nicotine
gum or transdermal nicotine is not a significant risk factor
for accelerating coronary artery disease or causing acute
cardiovascular events.
What are the implications of these studies for tobacco
control? One obvious question is whether snuff use has been
exonerated as a health concern. The answer is clearly no. It
should be noted that in Sweden nearly all smokeless tobacco
use is moist snuff, but in the U.S. both snuff and chewing
tobacco are used. All forms of smokeless tobacco have the
potential to cause oral cancer and other oral diseases, and
possibly some nonoral cancers (13). Oral cancer may be a
more significant problem with users of U.S. snuff as com-
pared with Swedish snuff because of higher nitrosamine
levels in U.S. snuff (14). Smokeless tobacco, especially
chewing tobacco, contains considerable sodium (as part of
an alkaline buffer to facilitate nicotine absorption). In one
study, individuals who chewed tobacco had an excess
sodium intake of 40 mEq/day, as compared with the same
individuals not chewing tobacco (3). Such a sodium load
could aggravate hypertension, congestive heart failure or
other edematous states. Finally, in the U.S. perhaps the
most serious concern about smokeless tobacco use is that in
adolescents snuff use facilitates the development of nicotine
addiction and predisposes adolescents to becoming adult
cigarette smokers (15).
A second tobacco control issue is the use of nicotine
medication to aid smoking cessation and for harm reduc-
tion. The data described previously, as well as other re-
search, indicate that medicinal nicotine is always safer than
cigarette smoking. Thus, the use of nicotine to aid smoking
cessation is warranted even in patients with active cardio-
vascular disease. The harm reduction concept includes the
use of medications for long periods to reduce or eliminate
smoking (16). The anticipated result would be a reduction
in smoking-related disease. This approach is similar to the
use of methadone maintenance to treat heroin addiction.
Harm reduction would be targeted at those smokers who are
unable to quit smoking but who would like to reduce the
health risks incurred by smoking cigarettes. There has been
some concern about enhanced toxicity from using nicotine
products and smoking at the same time. However, a recent
study from my laboratory involving individuals who used up
to three nicotine patches (63 mg) per day (the usual patch
dose is 15 to 21 mg/day), combined with ad libitum
cigarette smoking, showed no greater cardiovascular effect
of the combination as compared with cigarette smoking or
transdermal nicotine use alone (17). Thus, the available data
suggest that the risk of long-term nicotine exposure is low,
and the use of nicotine as a harm reduction strategy is a
reasonable idea. Clinical trials of long-term nicotine therapy
for harm reduction are clearly warranted.
Another harm reduction approach is the promotion of
potentially less hazardous cigarette-like delivery devices.
Two such products, the R.J. Reynolds Eclipse and the
Phillip Morris Accord, are being test-marketed in the
United States at this time. Both devices heat rather than
burn tobacco. The resultant smoke contains nicotine as well
as carbon monoxide, producing blood levels similar to those
derived from cigarette smoking (18). However, this smoke
contains much lower levels of oxidant gases, polynuclear
aromatic hydrocarbons and other combustion products. As
regulators of public health, policymakers consider whether
or not to support the use of such products, which includes
assessment of the relative safety of nicotine in the absence of
most of the oxidant gases and carcinogens. The available
data suggest that nicotine alone is reasonably safe, with the
caveat mentioned earlier that there may be differences in
effects between more rapidly and more slowly absorbed
nicotine. The hazards of carbon monoxide remain an
obvious concern. However, on balance, it seems worthwhile
to pursue further safety studies with these types of nicotine
delivery devices as a potential alternative to smoking in
those who cannot otherwise quit.
Finally, nicotine has also been proposed as a medication
for treatment of conditions such as ulcerative colitis, Alz-
heimer’s disease, Tourette’s syndrome and possibly attention
deficit disorder and affective disorders. The same safety
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considerations apply for nicotine therapy for medical dis-
eases as discussed for harm reduction.
In conclusion, nicotine is harmful primarily because it
sustains tobacco use. Tobacco use is harmful owing to toxic
combustion products, nicotine-derived nitrosamines and
various other tobacco additives. All tobacco use should be
discouraged. Nicotine itself may be potentially harmful in
certain individuals, with particular concern in pregnancy
and possibly in patients with acute cardiovascular disease
(1). However, nicotine is always less hazardous than using
tobacco. The Huhtasaari study and others reviewed in this
editorial comment support 1) the safety of using nicotine for
smoking cessation, even in patients with active cardiovas-
cular disease; 2) its use for harm reduction among recalci-
trant smokers; 3) further study of cigarette-like nicotine
delivery devices; and 4) the safety of conducting trials of
nicotine as a medication for medical diseases.
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